What is HC Wainwright’s Estimate for ONCY FY2027 Earnings?

Oncolytics Biotech Inc. (NASDAQ:ONCY) – Investment analysts at HC Wainwright increased their FY2027 earnings per share (EPS) estimates for Oncolytics Biotech in a research note issued on Monday, March 10th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings of ($0.08) per share for the year, up from their prior forecast of ($0.09). HC Wainwright currently has a “Buy” rating and a $5.00 target price on the stock. The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.28) per share. HC Wainwright also issued estimates for Oncolytics Biotech’s FY2028 earnings at $0.39 EPS.

A number of other equities research analysts also recently commented on the company. Royal Bank of Canada dropped their price objective on Oncolytics Biotech from $6.00 to $5.00 and set an “outperform” rating for the company in a report on Monday. Raymond James raised Oncolytics Biotech to a “moderate buy” rating in a research report on Thursday, November 14th. Maxim Group dropped their target price on Oncolytics Biotech from $5.00 to $3.00 and set a “buy” rating on the stock in a report on Monday. Finally, Leede Financial lowered Oncolytics Biotech from a “strong-buy” rating to a “moderate buy” rating in a research note on Wednesday, November 13th. Three equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $4.00.

Oncolytics Biotech Trading Up 2.8 %

NASDAQ ONCY opened at $0.63 on Thursday. The stock has a 50-day simple moving average of $0.77 and a 200 day simple moving average of $0.92. The company has a market capitalization of $53.87 million, a PE ratio of -2.33 and a beta of 1.18. Oncolytics Biotech has a 12 month low of $0.58 and a 12 month high of $1.53.

Hedge Funds Weigh In On Oncolytics Biotech

A number of large investors have recently made changes to their positions in the company. Virtu Financial LLC acquired a new stake in Oncolytics Biotech during the fourth quarter worth approximately $90,000. National Bank of Canada FI boosted its holdings in shares of Oncolytics Biotech by 199.6% in the 4th quarter. National Bank of Canada FI now owns 64,479 shares of the company’s stock valued at $60,000 after purchasing an additional 42,955 shares in the last quarter. Vantage Point Financial LLC acquired a new stake in shares of Oncolytics Biotech in the 4th quarter valued at $27,000. International Assets Investment Management LLC boosted its holdings in shares of Oncolytics Biotech by 15.0% during the 4th quarter. International Assets Investment Management LLC now owns 200,400 shares of the company’s stock valued at $186,000 after acquiring an additional 26,069 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of Oncolytics Biotech by 59.6% during the 4th quarter. Geode Capital Management LLC now owns 66,939 shares of the company’s stock valued at $61,000 after acquiring an additional 24,997 shares in the last quarter. Institutional investors own 6.82% of the company’s stock.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.